FIRST YEAR RESPONSE OF GROWTH IN SHORT CHILDREN WITH ACHONDROPLASIA OR HYPOCHONDROPLASIA TREATED WITH GROWTH HORMONE (GO)
FIRST YEAR RESPONSE OF GROWTH IN SHORT CHILDREN WITH ACHONDROPLASIA OR HYPOCHONDROPLASIA TREATED WITH GROWTH HORMONE (GO)
复制标题
患有软骨发育不全或软骨发育不全的矮个子儿童接受生长激素 (GO) 治疗后第一年的生长反应
DOI：
10.1203/00006450-199305001-00220
复制
发表时间：
1993
影响因子：
3.6
通讯作者：
N. Hertel
中科院分区：
文献类型：
--
作者：
L. Hagenäs;M. Ritzén;O. Eklöf;L. Neumeyer;B. Ollars;E. Karlsson;J. Müller;N. Hertel
骨骼发育不良常导致严重的身材矮小。传统上认为这对GH治疗没有反应。我们在此报告一组软骨发育不全或软骨发育不全儿童生长激素治疗后第一年的生长反应，纳入标准：身高<-2SD，年龄> 4岁且<10岁女孩，<12岁男孩。仅青春期前儿童纳入研究，与内源性GH水平无关。GH剂量随机分配至0.1或0.2 IU/kgx天，每周7天（Norditropin，诺和诺德）。治疗12个月后，记录以下生长参数。数据以平均值（SEM）表示。结论：12个月的GH治疗使软骨发育不全或软骨发育不良儿童的生长速度显著增加，而不会使身体比例失调恶化。GH剂量0.1或0.2 u/kg之间未观察到重大差异
Skeletal dysplosin often results in severe short stature. This has traditionally not been thought to respond to GH treatment. We here report the first year growth response to GH treatment of a group of children with achondro- or hypochondroplosia.Inclusion criteria: Height < -2SD, age >4yrs and <10yrs for girls and <12yrs for boys. Only prepubertal children were included in the study and irrespective of endogenous GH levels. The GH dose was randomised to 0.1 or 0.2 IU/kgxday, 7 days a week (Norditropin, Novo Nordisk). After 12 months of treatment the following growth parameters were recorded. Data is given as mean (SEM).Conclusion: 12 months of GH treatment gives a significant increase in growth velocity without worsening body disproportions in children with achondroplasia or hypochondroplasia. No major difference was seen between the GH doses 0.1 or 0.2 u/kg